Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $29,629.74 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider William Banyai sold 798 shares of the business's stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $29,629.74. Following the completion of the sale, the insider now owns 345,188 shares in the company, valued at $12,816,830.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

William Banyai also recently made the following trade(s):

• On Tuesday, April 2nd, William Banyai sold 327 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $10,705.98.

Twist Bioscience Price Performance

NASDAQ:TWST traded down $1.54 during mid-day trading on Tuesday, hitting $43.13. The company's stock had a trading volume of 1,808,210 shares, compared to its average volume of 997,886. The business's fifty day moving average is $34.11 and its two-hundred day moving average is $31.34. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -12.84 and a beta of 1.64. Twist Bioscience Co. has a 1 year low of $11.81 and a 1 year high of $44.92.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The firm had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. During the same period last year, the company earned ($1.06) earnings per share. Twist Bioscience's revenue for the quarter was up 25.1% compared to the same quarter last year. Analysts anticipate that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Evercore ISI increased their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an "outperform" rating in a research note on Friday. Robert W. Baird increased their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday. Scotiabank boosted their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a "sector outperform" rating in a research note on Monday. The Goldman Sachs Group raised shares of Twist Bioscience from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Finally, Barclays upped their target price on Twist Bioscience from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Friday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Twist Bioscience presently has a consensus rating of "Buy" and an average target price of $42.50.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently added to or reduced their stakes in TWST. ARK Investment Management LLC increased its position in shares of Twist Bioscience by 6.3% in the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company's stock valued at $265,881,000 after buying an additional 427,274 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in Twist Bioscience by 111.3% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company's stock valued at $137,241,000 after acquiring an additional 1,961,621 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Twist Bioscience by 2.9% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company's stock worth $132,086,000 after acquiring an additional 99,511 shares in the last quarter. Nikko Asset Management Americas Inc. raised its position in Twist Bioscience by 2.9% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company's stock worth $131,835,000 after acquiring an additional 99,511 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Twist Bioscience by 29.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company's stock worth $46,732,000 after purchasing an additional 284,884 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.